Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca : Drugmakers say UK could lose out on EU anti-counterfeit drugs push

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/07/2019 | 07:18pm EDT
FILE PHOTO: Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration

(Reuters) - Drugmakers warned on Friday that if Britain leaves the European Union without a deal next month Britons could miss out on an EU-wide system to fight counterfeit drugs that will go live on Saturday after years of British involvement in building it.

Drugmakers, wholesalers and pharmacies across Europe have worked for more than four years on a system based on a shared database and tamper-proof packages with barcodes that will go live on Saturday, to fulfil the European Union's Falsified Medicines Directive (FMD).

"It would be an absolute travesty if NHS patients aren't part of a system specifically designed to protect them. But that's exactly what could happen in a 'no deal' Brexit," Rick Greville, Director of Supply Chain at the Association of the British Pharmaceutical Industry (ABPI), said in a statement by the lobby group.

"It is just another reason why we urgently need a Brexit deal," he added.

The British government, which says that about three-quarters of medicines used by the state-run National Health Service (NHS) come via the EU, has outlined plans to ensure Britain has an extra six weeks of drug supplies in the event of a no-deal Brexit.

The global counterfeit drug market is worth around $200 billion (£154 billion) annually, the World Health Organisation says, with often devastating consequences for unsuspecting patients, many of whom live in the developing world.

The problem was highlighted in October by coordinated police raids in 116 countries that netted 500 tonnes of illicit pharmaceuticals available online, including fake cancer medications and pain pills.

The European Medicines Verification System (EMVS) will allow dispensing pharmacists to scan drug packages and link up to a database to give patients assurance on the product's authenticity.

The European Union said on Thursday it would work with Theresa May on whether a way could be found to avoid the disruption of a no-deal Brexit on March 29, after the British prime minister demanded changes to the divorce deal to get it through parliament.

The highly regulated drugs sector is seen as one of the most vulnerable to a no-deal outcome due to its pan-European supply chains and need for regulatory oversight.

(Reporting by Ludwig Burger; Editing by Frances Kerry)

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA 0.07% 5912 Delayed Quote.0.60%
GLAXOSMITHKLINE 0.77% 1552.4 Delayed Quote.3.30%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
04/23LONDON STOCK EXCHANGE : Oil heavyweights, exporters guide FTSE 100 close to seve..
RE
04/23ASTRAZENECA PLC : quaterly earnings release
04/18LONDON STOCK EXCHANGE : FTSE 100 dips on sluggish euro zone PMI, Unilever sparkl..
RE
04/17London's shares off six-month highs, Bunzl suffers worst day in a decade
RE
04/15LONDON STOCK EXCHANGE : London's FTSE 100 subdued, IWG lifts midcaps
RE
04/15LONDON STOCK EXCHANGE : London's FTSE 100 tugged down by miners; IWG lifts midca..
RE
04/10ASTRAZENECA : Lynparza approved in EU for the treatment of germline BRCA-mutated..
PU
04/10ASTRAZENECA : Lynparza Approved in EU to Treat a Form of Breast Cancer
DJ
04/10ASTRAZENECA : Lynparza approved in EU for the treatment of germline BRCA-mutated..
AQ
04/04ASTRAZENECA : Positive results from Fasenra Phase II trial in hypereosinophilic ..
PU
More news
Financials ($)
Sales 2019 23 512 M
EBIT 2019 6 331 M
Net income 2019 3 025 M
Debt 2019 11 994 M
Yield 2019 3,65%
P/E ratio 2019 35,83
P/E ratio 2020 26,08
EV / Sales 2019 4,79x
EV / Sales 2020 4,35x
Capitalization 101 B
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 85,6 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Shriti Vadera Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA0.60%100 727
JOHNSON & JOHNSON8.41%372 522
ROCHE HOLDING LTD.9.68%227 039
PFIZER-9.69%218 852
NOVARTIS7.44%195 750
MERCK AND COMPANY-2.20%192 697